NCT02649400

Brief Summary

This study assesses the impact of diastolic heart failure on exercise capacity in women who have a previous coronary condition. All the participants will go through the same evaluation.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2013

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

December 2, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 7, 2016

Completed
Last Updated

January 12, 2016

Status Verified

January 1, 2016

Enrollment Period

1 year

First QC Date

December 2, 2015

Last Update Submit

January 8, 2016

Conditions

Outcome Measures

Primary Outcomes (3)

  • Functional Capacity

    Measured by the distance walked in the six-minute walking test in meters.

    Up to 1 year after diagnosis

  • Inflammatory markers

    Inflammatory markers evaluated using specific assays for blood analysis Interleukin (IL) 1 (pg/mL), IL-6 (pg/mL), IL 8 (pg/mL),Tumor Necrosis Factor alpha (pg/mL), Brain Natriuretic Peptide (BNP) (pg/mL), pro-BNP (pg/mL); Lab results will be analysed for each marker and values will be compared to laboratory reference data to identify values out of range.

    Up to 1 year after diagnosis on the same day as functional capacity assessment

  • Inflammatory Markers

    Inflammatory markers evaluated using specific assays for blood analysis for high sensitivity C reactive protein (mg/L), alpha-1-acid glycoprotein (mg/dL) and platelets (platelets/cubic millimeters), lactate (mg/dL), uric acid (mg/dL)

    Up to 1 year after diagnosis on the same day as functional capacity assessment

Secondary Outcomes (5)

  • Heart autonomic function

    Up to 1 year after diagnosis on the same day as functional capacity assessment

  • Quality of life

    Up to 1 year after diagnosis on the same day as functional capacity assessment

  • Pulmonary function

    Up to 1 year after diagnosis on the same day as functional capacity assessment

  • Respiratory muscle strength

    Up to 1 year after diagnosis on the same day as functional capacity assessment

  • Peripheral muscle strength

    Up to 1 year after diagnosis on the same day as functional capacity assessment

Study Arms (1)

Diastolic Heart Failure

Women with diastolic heart failure and previous coronary artery disease

Eligibility Criteria

Age35 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women with coronary artery disease diagnosed through angiography and heart failure with preserved ejection fraction diagnosed via ecocardiography.

You may qualify if:

  • Women;
  • Aged between 35 and 70 years;
  • Coronary artery disease proven by coronary angiography;
  • Diastolic heart failure confirmed by recent echocardiography (6 months);
  • Left Ventricle ejection fraction of greater than 50%;
  • Absence of acute or chronic pulmonary disease;
  • Patient clinically compensated;
  • Consent form signed for participation in the research

You may not qualify if:

  • Inability to perform spirometry;
  • Presence of acute or chronic pulmonary disease;
  • Chronic inflammatory disease, kidney or liver disease;
  • Patients using corticosteroids, aspirin or other nonsteroidal anti-inflammatory;
  • Clinical or laboratory evidence of infection;
  • Morbid obesity;
  • Hemodynamic instability at the time of spirometry;
  • Patient's or legal guardian request to leave at any time of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Federal University of Sao Paulo

São Paulo, São Paulo, 04024002, Brazil

Location

Biospecimen

Retention: SAMPLES WITH DNA

Venous blood and plasma.

MeSH Terms

Conditions

Heart Failure, DiastolicCoronary Artery DiseaseInflammation

Condition Hierarchy (Ancestors)

Heart FailureHeart DiseasesCardiovascular DiseasesCoronary DiseaseMyocardial IschemiaArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Daniel Figueiredo Alves da Silva, PT

    Federal University of São Paulo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Post-graduate Student

Study Record Dates

First Submitted

December 2, 2015

First Posted

January 7, 2016

Study Start

August 1, 2013

Primary Completion

August 1, 2014

Last Updated

January 12, 2016

Record last verified: 2016-01

Data Sharing

IPD Sharing
Will not share

Locations